Search
Search
{{#data.error.root_cause}}
{{/data.error}}
{{^data.error}}
[{{{type}}}] {{{reason}}}
{{/data.error.root_cause}}
{{#data.hits.hits}}
{{#_source.featured}}
FEATURED
{{/_source.featured}}
{{#_source.showImage}}
{{#_source.image}}
{{/_source.image}}
{{/_source.showImage}}
{{/data.hits.hits}}
{{{_source.title}}} {{#_source.showPrice}} {{{_source.displayPrice}}} {{/_source.showPrice}}
{{#_source.showLink}} {{/_source.showLink}} {{#_source.showDate}}{{{_source.displayDate}}}
{{/_source.showDate}}{{{_source.description}}}
{{#_source.additionalInfo}}{{#_source.additionalFields}} {{#title}} {{{label}}}: {{{title}}} {{/title}} {{/_source.additionalFields}}
{{/_source.additionalInfo}}Anti-mAB-M | Mouse anti-human Abeta protein (3-10) region, oligomer-specific (clone 2D10,F6)
(Cat#: AS13 2716)
Description
- Immunogen: Synthetic peptide chosen from human Abeta protein (3-10) pregion, oligomer specific
- Host: Mouse
- Clonality: Monoclonal
- Purity: Immunogen affinity purified serum in PBS pH 7.4.
- Format: Lyophilized
- Quantity: 50 µg
- Reconstitution: For reconstitution add 50 µl of sterile water
- Storage: For short-term storage, please add sodium azide and srote at +4°C. For long-term storage, store lyophilized/reconstituted at -20°C; once reconstituted make aliquots to avoid repeated freeze-thaw cycles. Please remember to spin the tubes briefly prior to opening them to avoid any losses that might occur from material adhering to the cap or sides of the tube.
- Tested applications: Dot blot (Dot), ELISA (ELISA), Immunolocalization (IL)
- Recommended dilutions: 10 µg/ml (IL), 1-2 µg/ml (Dot), 2-4 µg/ml (ELISA capture)
- Expected | apparent MW: 4.5 kDa
- Confirmed reactivity: Human
- Not reactive in: No confirmed exceptions from predicted reactivity are currently known
- Alzheimer's disease (AD) is the most prevalent neurodegenerative disease in the growing population of elderly people. A hallmark of AD is the accumulation of plaques in the brain of AD patients. The plaques predominantly consist of aggregates of amyloid-beta (Abeta), a peptide of 39-42 amino acids generated in vivo by specific, proteolytic cleavage of the amyloid precursor protein. Recent findings however suggest that smaller oligomeric forms of Abeta, formed in parallel to the amyloid plaques, excert the predominant tissue damaging effect.Specific identification of the oligomeric forms is as a consequence of great interest. Based on a recently published technique a highly oligomer-specific antibody (mAB-M), targeting Abeta oligomers while omitting reactivity towards the monomeric and fibrillar counterpart, has been developed.
- Meilandt et al. (2019). Characterization of the selective in vitro and in vivo binding properties of crenezumab to oligomeric A[beta]. Alzheimers Res Ther. 2019 Dec 1;11(1):97. doi: 10.1186/s13195-019-0553-5.Brännström et al. (2014). A Generic Method for Design of Oligomer-Specific Antibodies. PLoS ONE. DOI: 10.1371/journal.pone.0090857.
- Immunolocalization: human tissue was paraffin-embedded and sectioned. De-waxed and rehydrated in an ethanol gradient. Antigens were retrieved in sodium citrate buffer (pH 6) at 95°C for 1 h. The tissue sections were separately incubated for 1 h at RT with primary antibody and antibody binding was visualized with IgG Preoxidase Reagent Kit.This antibody is specific for human Amyloid-Beta oligomers.